Italia markets closed
  • Business Wire

    Taos Welcomes Gopal Bhat as Senior Vice President of Product and International Strategy

    Today, Taos, a cloud professional and managed services leader, announced Gopal Bhat as Senior Vice President of Product and International Strategy. Mr. Bhat brings a breadth of technology expertise, product innovation, and global operations as Taos continues to expand its global leadership in cloud and DevOps.

  • SVB Financial Group Announces Availability Of Quarterly Financial Results
    PR Newswire

    SVB Financial Group Announces Availability Of Quarterly Financial Results

    SVB Financial Group (NASDAQ: SIVB) has released its financial results for the quarter ended September 30, 2020. Please visit SVB's Investor Relations website at http://ir.svb.com to view the earnings release, and summary earnings letter and presentation.

  • Genocea to Host Third Quarter 2020 Corporate Update Conference Call & Webcast
    GlobeNewswire

    Genocea to Host Third Quarter 2020 Corporate Update Conference Call & Webcast

    CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its third quarter 2020 financial results and corporate update conference call and live audio webcast on Thursday, October 29th at 8:30 a.m. EDT.Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 5951388. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-and-presentations.A webcast replay will be available on the Genocea website beginning approximately two hours after the event and will be archived for 90 days.About Genocea Biosciences, Inc. Genocea’s mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient’s T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood for which we are commencing a Phase 1/2a clinical trial. To learn more, please visit www.genocea.com.Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Genocea's Annual Report on Form 10-K for the year ended December 31, 2019 and any subsequent SEC filings. These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements, except as may be required by law.Investor Contact: Dan Ferry 617-430-7576 daniel@lifesciadvisors.com